Evaluating the Preclinical Efficacy of Photobiomodulation in Alleviating Neuropathic Corneal Pain: A Behavioral Study

Abstract

Purpose

Neuropathic corneal pain (NCP) is a debilitating condition characterized by persistent pain due to corneal nerve damage or dysfunction. Millions of individuals and their families endure the significant impact of chronic pain. Effective management strategies are crucial yet limited, prompting the exploration of innovative treatments such as photobiomodulation (PBM).

Design

In vivo preclinical therapeutics investigation in mice.

Subjects

Thy1-YFP mice.

Methods

This study evaluates the efficacy of PBM in treating NCP across 4 animal models: normal control, sham control, pulled nerve, and full transection (FT). Behavioral assessments, including the von Frey test (VFT) for mechanical sensitivity and the eye-wiping test (EWT) for chemical sensitivity, were employed to evaluate the therapeutic impact of PBM till day 56 (D-1, D1, D3, D5, D7, D14, D28, D42, and D56).

Main Outcome Measures

Advances in therapeutic approach for NCP through the potential of PBM.

Results

Photobiomodulation significantly reduced behavioral manifestations of pain in the pulled nerve model (VFT: no PBM [D1 = 0.043 ± 0.044, D56 = 0.05 ± 0.014] and PBM [D1 = 0.050 ± 0.008 {P value = 0.18}, D56 = 0.09 ± 0.014 {P value = 0.02}], EWT: no PBM [D1 = 11.96 ± 0.47, D56 = 12.11 ± 0.15] and PBM [D1 = 11.73 ± 0.18 {P value = 0.2}, D56 = 11.22 ± 0.31] [P value = 0.01]) and FT model (VFT: no PBM [D1 = 0.022 ± 0.0028, D56 = 0.023 ± 0.0047] and PBM [D1 = 0.024 ± 0.0028 {P value = 0.2}, D56 = 0.073 ± 0.0094] [P value = 0.02]), EWT: no PBM [D1 = 13.1 ± 0.14, D56 = 13.36 ± 0.30] and PBM [D1 = 12.86 ± 0.41, {P value = 0.2}, D56 = 12.53 ± 0.41] [P value = 0.04]}, suggesting an effective reduction of pain sensitivity and an increase in corneal nerve function. The temporal patterns also suggest that early intervention with PBM, initiated shortly after nerve injury, may be crucial for preventing the chronic progression of NCP.

Conclusions

These outcomes support PBM as a promising nonpharmacologic intervention for NCP; this not only reinforces the potential of PBM in NCP treatment but also provides a foundation for future clinical applications in managing corneal neuropathy.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.